Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders Collaboration provides opportunity to expand on Alexion’s two decades ...

The complement system is activated in many rheumatic diseases, as evident from deposition of activation fragments in affected tissue, decreased residual complement function and increased levels of ...

- Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway - - Zealand Pharma to receive ...